Methodology
Introduction
Diagnosis, pathology and molecular classification
Recommendations
Differentiated thyroid cancer
Surgical treatment
Recommendations
Category, grade | Definition |
---|---|
Strength of recommendation | |
A | Good evidence to support a recommendation for use |
B | Moderate evidence to support a recommendation for use |
C | Poor evidence to support a recommendation |
D | Moderate evidence to support a recommendation against use |
E | Good evidence to support a recommendation against use |
Quality of evidence | |
I | Evidence from ≥ 1 properly randomized, controlled trial |
II | Evidence from ≥ 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from > 1 center); from multiple time series; or from dramatic results from uncontrolled experiments |
III | Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees |
Staging and risk classification
T Category | T Criteria |
---|---|
Definition of primary tumor (T) for papillary and follicular thyroid carcinomas | |
TX | Primary tumor cannot be assessed |
T0 | No evidence of primary tumor |
T1 | Tumor ≤ 2 cm in greatest dimension limited to the thyroid |
T1a | Tumor ≤ 1 cm in greatest dimension limited to the thyroid |
T1b | Tumor > 1 cm but ≤ 2 cm in greatest dimension, limited to the thyroid |
T2 | Tumor > 2 cm but ≤ 4 cm in greatest dimension limited to the thyroid |
T3* | Tumor > 4 cm limited to the thyroid, or gross extrathyroidal extension invading only strap muscles |
T3a* | Tumor > 4 cm limited to the thyroid |
T3b* | Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size |
T4 | Includes gross extrathyroidal extension into major neck structures |
T4a | Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size |
T4b | Gross extrathyroidal extension invading prevertebral fascia or encasing carotid artery or mediastinal vessels from a tumor of any size |
N Category | N Criteria |
---|---|
Definition of regional lymph node (N) | |
NX | Regional lymph nodes cannot be assessed |
N0 | No evidence of regional lymph nodes metastasis |
N0a* | One or more cytological or histologically confirmed benign lymph node |
N0b* | No radiologic or clinical evidence of locoregional lymph node metastasis |
N1* | Metastasis to regional nodes |
N1a* | Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease |
N1b* | Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (Levels I, II, III, IV, or V) or retropharyngeal lymph nodes |
M Category | M Criteria |
---|---|
Definition of distant metastasis (M) | |
M0 | No distant metastasis |
M1 | Distant metastasis |
When age at diagnosis is… | And T is… | And N is… | And M is… | Then the stage group is… |
---|---|---|---|---|
< 55 years | Any T | Any N | M0 | I |
Any T | Any N | M1 | II | |
≥ 55 years | T1 | N0/NX | M0 | I |
T1 | N1 | M0 | II | |
T2 | N0/NX | M0 | I | |
T2 | N1 | M0 | II | |
T3a/T3b | Any N | M0 | II | |
T4a | Any N | M0 | III | |
T4b | Any N | M0 | IVA | |
Any T | Any N | M1 | IVB |
Low risk |
---|
Papillary thyroid cancer with all of the following present: |
No local or distant metastases |
All macroscopic tumor has been resected |
No invasion of locoregional tissues |
Tumor does not have aggressive histology (aggressive histologies include tall cell, insular, columnar cell carcinoma, Hürthle cell carcinoma, follicular thyroid cancer, hobnail variant) |
No vascular invasion |
No 131I uptake outside the thyroid bed on the post-treatment scan, if done |
Clinical N0 or ≤ 5 pathologic N1 micrometastases (< 0.2 cm in largest dimension)* |
Intrathyroidal, encapsulated follicular variant of papillary thyroid cancer* |
Intrathyroidal, well-differentiated follicular thyroid cancer with capsular invasion and no or minimal (< 4 foci) vascular invasion* |
Intrathyroidal, papillary microcarcinoma, unifocal or multifocal, including BRAF V600E mutated (if known)* |
Intermediate risk |
Any of the following present: |
Microscopic invasion into the perithyroidal soft tissues |
Cervical lymph node metastases or 131I avid metastatic foci in the neck on the post-treatment scan done after thyroid remnant ablation |
Tumor with aggressive histology or vascular invasion (aggressive histologies include tall cell, insular, columnar cell carcinoma, Hürthle cell carcinoma, follicular thyroid cancer, hobnail variant) |
Clinical N1 or > 5 pathologic N1 with all involved lymph nodes < 3 cm in largest dimension* |
Multifocal papillary thyroid microcarcinoma with extrathyroidal extension and BRAF V600E mutated (if known)* |
High risk |
Any of the following present: |
Macroscopic tumor invasion |
Incomplete tumor resection with gross residual disease |
Distant metastases |
Postoperative serum thyroglobulin suggestive of distant metastases |
Pathologic N1 with any metastatic lymph node ≥ 3 cm in largest dimension* |
Follicular thyroid cancer with extensive vascular invasion (> 4 foci of vascular invasion)* |